A key player in a powerful research ecosystem

The CaixaResearch Institute's scientific programme will take advantage of synergies with centres associated with ”la Caixa” Foundation to achieve maximum impact

The CaixaResearch Institute will carry out its own scientific programme of maximum impact but it will also generate a stable ecosystem for collaboration between the four leading centres with which ”la Caixa” Foundation has a particular connection: the IrsiCaixa AIDS Research Institute, the Barcelona Institute for Global Health (ISGlobal), the Vall d’Hebron Institute of Oncology (VHIO) and the Barcelonaβeta Brain Research Center (BBRC).

This collaborative model will enhance pre-existing cooperative efforts, promote new synergies between the different scientific communities and make available to these four centres the great potential offered by the CaixaResearch Institute's scientific and technical resources.

Collaboration with research centres

  • 1. CaixaResearch Institute

    The CaixaResearch Institute will be dedicated to the translational study of immunology and disease from an interdisciplinary perspective, through the development of innovative and cutting-edge technologies and including an analysis of the contribution made by the exposome.

  • 2. Barcelonaβeta Brain Research Center (BBRC)

    The BBRC is an institute dedicated to preventing Alzheimer's disease and studying the cognitive functions affected in healthy and pathological ageing.

  • 3. IrsiCaixa AIDS Research Institute

    IrsiCaixa carries out research to eradicate HIV/AIDS and related diseases, as well as other current biomedical challenges such as the study of the microbiome and emerging infectious diseases.

  • 4. Barcelona Institute for Global Health (ISGlobal)

    ISGlobal aims to improve global health and promote health equality through excellence in research and the transfer and application of knowledge.

  • 5. Vall d'Hebron Institute of Oncology (VHIO)

    VHIO is a comprehensive oncological centre where scientists and doctors adopt a purely translational research model, working together in multidisciplinary teams to accelerate and advance the field of personalised and targeted cancer therapies.